Skip to content
The World of International Organizations
  • Home
  • About Us
  • Archives
  • Sign Up
  • twittericon
  • facebookicon
  • linkedinicon
  • Reset
News

Vaccine approvals add promise for COVAX use

Britain and Argentina authorized emergency use of a coronavirus vaccine that adds momentum to its anticipated global use by international organizations.

Print Friendly, PDF & Email
By Arete News - December 30, 2020
A registered nurse at the U.S. Naval Medical Center in San Diego administers a shot to a patient for the Phase III trial of AstraZeneca’s COVID-19 vaccine candidate (AN/Jake Greenberg)
You need to login to view this content. Please Login. Not a Member? Join Us

Related Articles

  • Vaccine nationalism hangs over 2021 recovery
    Vaccine nationalism hangs over 2021 recovery
    Richer countries locked up most of 2021's COVID-19 vaccine supply despite the COVAX Facility's multilateral…
  • Delays foreseen with COVAX vaccine deliveries
    Delays foreseen with COVAX vaccine deliveries
    International organizations acknowledged significant delays in delivering COVID-19 vaccines to poor nations due to pressure…
  • WHO urges end to bilateral vaccine deals
    WHO urges end to bilateral vaccine deals
    The head of the U.N. health agency asked wealthy countries to stop hoarding most of…
  • WHO grants emergency use of China's Sinopharm
    WHO grants emergency use of China's Sinopharm
    WHO added a Chinese shot to its list of COVID-19 vaccines approved for emergency use,…
  • WHO adds vaccines for emergency use
    WHO adds vaccines for emergency use
    WHO listed two of AstraZeneca’s coronavirus vaccines for emergency use, only the second instance of…
  • COVAX vaccine rollout gets 2 billion doses
    COVAX vaccine rollout gets 2 billion doses
    The COVAX Facility has secured almost 2 billion doses of COVID-19 vaccine candidates for low-income…

About Us   Archives    News    In Depth    Under The Radar    How It Works   Data

Terms of Service   |   Privacy Policy

© Arete News

Design & Development by Vast.dev